PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.
⁃ To be eligible to participate in this study, an individual must meet all the following criteria:
• Patient is at least 18 years of age at the time of study enrollment.
• Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).
• Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
• Patient is willing and able to provide informed consent to participate in this study.